Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations

Joeva J. Barrow, Eduardo Balsa, Francisco Verdeguer, Clint D J Tavares, Meghan S. Soustek, Louis R. Hollingsworth, Mark Jedrychowski, Rutger Vogel, Joao A. Paulo, Jan Smeitink, Steve P. Gygi, John Doench, David E. Root, Pere Puigserver

Research output: Contribution to journalArticle

Abstract

Mitochondrial diseases comprise a heterogeneous group of genetically inherited disorders that cause failures in energetic and metabolic function. Boosting residual oxidative phosphorylation (OXPHOS) activity can partially correct these failures. Herein, using a high-throughput chemical screen, we identified the bromodomain inhibitor I-BET 525762A as one of the top hits that increases COX5a protein levels in complex I (CI) mutant cybrid cells. In parallel, bromodomain-containing protein 4 (BRD4), a target of I-BET 525762A, was identified using a genome-wide CRISPR screen to search for genes whose loss of function rescues death of CI-impaired cybrids grown under conditions requiring OXPHOS activity for survival. We show that I-BET525762A or loss of BRD4 remodeled the mitochondrial proteome to increase the levels and activity of OXPHOS protein complexes, leading to rescue of the bioenergetic defects and cell death caused by mutations or chemical inhibition of CI. These studies show that BRD4 inhibition may have therapeutic implications for the treatment of mitochondrial diseases.

Original languageEnglish (US)
Pages (from-to)163-175
Number of pages13
JournalMolecular Cell
Volume64
Issue number1
DOIs
StatePublished - Oct 6 2016
Externally publishedYes

Fingerprint

Mitochondrial Diseases
Energy Metabolism
Oxidative Phosphorylation
Mutation
Proteins
Clustered Regularly Interspaced Short Palindromic Repeats
Proteome
Cell Death
Genome
Genes

Keywords

  • BRD4
  • bromodomain inhibitors
  • mitochondria
  • mitochondrial disorders
  • OXPHOS
  • PGC-1α

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Barrow, J. J., Balsa, E., Verdeguer, F., Tavares, C. D. J., Soustek, M. S., Hollingsworth, L. R., ... Puigserver, P. (2016). Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. Molecular Cell, 64(1), 163-175. https://doi.org/10.1016/j.molcel.2016.08.023

Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. / Barrow, Joeva J.; Balsa, Eduardo; Verdeguer, Francisco; Tavares, Clint D J; Soustek, Meghan S.; Hollingsworth, Louis R.; Jedrychowski, Mark; Vogel, Rutger; Paulo, Joao A.; Smeitink, Jan; Gygi, Steve P.; Doench, John; Root, David E.; Puigserver, Pere.

In: Molecular Cell, Vol. 64, No. 1, 06.10.2016, p. 163-175.

Research output: Contribution to journalArticle

Barrow, JJ, Balsa, E, Verdeguer, F, Tavares, CDJ, Soustek, MS, Hollingsworth, LR, Jedrychowski, M, Vogel, R, Paulo, JA, Smeitink, J, Gygi, SP, Doench, J, Root, DE & Puigserver, P 2016, 'Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations', Molecular Cell, vol. 64, no. 1, pp. 163-175. https://doi.org/10.1016/j.molcel.2016.08.023
Barrow JJ, Balsa E, Verdeguer F, Tavares CDJ, Soustek MS, Hollingsworth LR et al. Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. Molecular Cell. 2016 Oct 6;64(1):163-175. https://doi.org/10.1016/j.molcel.2016.08.023
Barrow, Joeva J. ; Balsa, Eduardo ; Verdeguer, Francisco ; Tavares, Clint D J ; Soustek, Meghan S. ; Hollingsworth, Louis R. ; Jedrychowski, Mark ; Vogel, Rutger ; Paulo, Joao A. ; Smeitink, Jan ; Gygi, Steve P. ; Doench, John ; Root, David E. ; Puigserver, Pere. / Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. In: Molecular Cell. 2016 ; Vol. 64, No. 1. pp. 163-175.
@article{35d06d9eebe746e794b2f031bde45497,
title = "Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations",
abstract = "Mitochondrial diseases comprise a heterogeneous group of genetically inherited disorders that cause failures in energetic and metabolic function. Boosting residual oxidative phosphorylation (OXPHOS) activity can partially correct these failures. Herein, using a high-throughput chemical screen, we identified the bromodomain inhibitor I-BET 525762A as one of the top hits that increases COX5a protein levels in complex I (CI) mutant cybrid cells. In parallel, bromodomain-containing protein 4 (BRD4), a target of I-BET 525762A, was identified using a genome-wide CRISPR screen to search for genes whose loss of function rescues death of CI-impaired cybrids grown under conditions requiring OXPHOS activity for survival. We show that I-BET525762A or loss of BRD4 remodeled the mitochondrial proteome to increase the levels and activity of OXPHOS protein complexes, leading to rescue of the bioenergetic defects and cell death caused by mutations or chemical inhibition of CI. These studies show that BRD4 inhibition may have therapeutic implications for the treatment of mitochondrial diseases.",
keywords = "BRD4, bromodomain inhibitors, mitochondria, mitochondrial disorders, OXPHOS, PGC-1α",
author = "Barrow, {Joeva J.} and Eduardo Balsa and Francisco Verdeguer and Tavares, {Clint D J} and Soustek, {Meghan S.} and Hollingsworth, {Louis R.} and Mark Jedrychowski and Rutger Vogel and Paulo, {Joao A.} and Jan Smeitink and Gygi, {Steve P.} and John Doench and Root, {David E.} and Pere Puigserver",
year = "2016",
month = "10",
day = "6",
doi = "10.1016/j.molcel.2016.08.023",
language = "English (US)",
volume = "64",
pages = "163--175",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations

AU - Barrow, Joeva J.

AU - Balsa, Eduardo

AU - Verdeguer, Francisco

AU - Tavares, Clint D J

AU - Soustek, Meghan S.

AU - Hollingsworth, Louis R.

AU - Jedrychowski, Mark

AU - Vogel, Rutger

AU - Paulo, Joao A.

AU - Smeitink, Jan

AU - Gygi, Steve P.

AU - Doench, John

AU - Root, David E.

AU - Puigserver, Pere

PY - 2016/10/6

Y1 - 2016/10/6

N2 - Mitochondrial diseases comprise a heterogeneous group of genetically inherited disorders that cause failures in energetic and metabolic function. Boosting residual oxidative phosphorylation (OXPHOS) activity can partially correct these failures. Herein, using a high-throughput chemical screen, we identified the bromodomain inhibitor I-BET 525762A as one of the top hits that increases COX5a protein levels in complex I (CI) mutant cybrid cells. In parallel, bromodomain-containing protein 4 (BRD4), a target of I-BET 525762A, was identified using a genome-wide CRISPR screen to search for genes whose loss of function rescues death of CI-impaired cybrids grown under conditions requiring OXPHOS activity for survival. We show that I-BET525762A or loss of BRD4 remodeled the mitochondrial proteome to increase the levels and activity of OXPHOS protein complexes, leading to rescue of the bioenergetic defects and cell death caused by mutations or chemical inhibition of CI. These studies show that BRD4 inhibition may have therapeutic implications for the treatment of mitochondrial diseases.

AB - Mitochondrial diseases comprise a heterogeneous group of genetically inherited disorders that cause failures in energetic and metabolic function. Boosting residual oxidative phosphorylation (OXPHOS) activity can partially correct these failures. Herein, using a high-throughput chemical screen, we identified the bromodomain inhibitor I-BET 525762A as one of the top hits that increases COX5a protein levels in complex I (CI) mutant cybrid cells. In parallel, bromodomain-containing protein 4 (BRD4), a target of I-BET 525762A, was identified using a genome-wide CRISPR screen to search for genes whose loss of function rescues death of CI-impaired cybrids grown under conditions requiring OXPHOS activity for survival. We show that I-BET525762A or loss of BRD4 remodeled the mitochondrial proteome to increase the levels and activity of OXPHOS protein complexes, leading to rescue of the bioenergetic defects and cell death caused by mutations or chemical inhibition of CI. These studies show that BRD4 inhibition may have therapeutic implications for the treatment of mitochondrial diseases.

KW - BRD4

KW - bromodomain inhibitors

KW - mitochondria

KW - mitochondrial disorders

KW - OXPHOS

KW - PGC-1α

UR - http://www.scopus.com/inward/record.url?scp=84994173232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994173232&partnerID=8YFLogxK

U2 - 10.1016/j.molcel.2016.08.023

DO - 10.1016/j.molcel.2016.08.023

M3 - Article

C2 - 27666594

AN - SCOPUS:84994173232

VL - 64

SP - 163

EP - 175

JO - Molecular Cell

JF - Molecular Cell

SN - 1097-2765

IS - 1

ER -